Levitee Labs Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Bentil
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 800 West Pender Street Vancouver BC Canada V6C 1J8
- IPO Date
- Aug 12, 2021
- Website
- leviteelabs.com
- Similar Companies
- Business
- Levitee Labs Inc. engages in the development and commercialization of integrated health and wellness products, with a focus on advanced therapeutic and personal care solutions. The company’s core offerings include bioactive skincare products; nutraceutical supplements; innovative wound care and dermatological treatment products; and digital health platforms for personalized wellness management. Levitee Labs markets its products primarily in North America, Europe, and select international regions. Founded in 2014 and headquartered in Toronto, Canada, Levitee Labs serves a diverse customer base comprising healthcare providers, wellness consumers, and retail partners. Recent major developments include strategic partnerships in 2024 to expand its digital health platform capabilities and enhance personalized virtual wellness services. The company has also launched several new product lines in bioactive skincare and wound care during the last two years, reflecting a significant expansion of its product portfolio and R&D focus. Additionally, Levitee Labs secured a substantial funding round in 2024 to accelerate its market expansion efforts and invest in next-generation health technology solutions. These changes underscore its commitment to integrating cutting-edge science with consumer wellness applications and expanding its footprint in global health markets. Overall, Levitee Labs operates within the healthcare and wellness industry segments, emphasizing innovation in therapeutic products and digital health services. The company leverages its proprietary technology platforms and research partnerships to maintain a competitive edge and deliver comprehensive wellness solutions to a broad customer spectrum across multiple geographies. Its headquarters in Toronto anchors its principal R&D and commercial operations while supporting a growing international presence.
CSE Bulletin: Delist - Levitee Labs Inc. (LVT)
Levitee Labs announces completion of Earth Circle sale; amends financing terms with RiverFort Global Opportunities
Levitee Labs appoints economist David Bentil as chief executive officer
Levitee Labs appoints Philip van den Berg as its new interim CEO; closes first tranche of its private placement
Levitee Labs announces non-brokered private placement of up to C$3M
Levitee Labs inks retail distribution agreement with Body Energy Club for MONKE Nutraceuticals
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
Levitee Labs partners with Canntab Therapeutics to provide alternative to drugs amid opioid crisis in Canada
Levitee Labs forms medical advisory board and welcomes six new members
Levitee Labs looking to be world's first listed psychedelic company with significant revenue and cashflow
Levitee Labs collaborates with LiveRx Research to test, treat and cure Hepatitis C; provide equitable access throughout Alberta, Canada
Levitee Labs announces appointment of Noha ElSayed as its executive director, Levitee Clinics and Levitee Pharmacies, Alberta Region
Levitee Labs signs letter of intent to acquire a chain of specialty addiction pharmacies in British Columbia
Levitee Labs seeing consistent growth across all its divisions
Levitee Labs to buy 51% of Alberta-based Compounding Pharmacy for production of intranasal ketamine, capsules under company brand